CAPTRUST Financial Advisors’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-36	Closed	-$4K	–	2059
2019 Q3	$4K	Hold	36	–	–	﹤0.01%	1717
2019 Q2	$3K	Buy	+36	New	+$3.39K	﹤0.01%	1769

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors's CBPO Position: Q4 2019 in Review

CAPTRUST Financial Advisors sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2019, closing a stake of 36 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in CBPO in Q2 2019 and held it in 2 quarters. The position peaked at $4K in Q3 2019. 87 funds tracked by Wall St. Rank hold CBPO as of Q4 2019.

CAPTRUST Financial Advisors reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2019 after selling out during the quarter.
CAPTRUST Financial Advisors sold 36 China Biologic Products Holdings, Inc. shares in Q4 2019, an estimated $4K.
CAPTRUST Financial Advisors first reported a position in China Biologic Products Holdings, Inc. in Q2 2019 and held it in 2 quarters.
CAPTRUST Financial Advisors's China Biologic Products Holdings, Inc. position peaked at $4K in Q3 2019.
87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2019.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.